Document is current
Any future updates will be listed below
-
Authors
La, Elizabeth M. https://orcid.org/0000-0001-5652-8961
Sweeney, Carolyn https://orcid.org/0000-0002-1538-5893
Davenport, Eric https://orcid.org/0000-0002-2461-7000
Calhoun, Sarah https://orcid.org/0000-0001-6308-3622
Harmelink, Andrea https://orcid.org/0009-0008-6255-5147
Singer, David https://orcid.org/0000-0001-8008-8003
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 21 February 2025
First Online: 14 March 2025
Declarations
:
: Elizabeth La, Andrea Harmelink, and David Singer are employed by and hold financial equities in GSK. Carolyn Sweeney, Eric Davenport, and Sarah Calhoun are employed by RTI Health Solutions, which received funding from GSK for the conduct of this study. All authors declare no other financial and non-financial relationships and activities.
: The study’s eligible participants were required to provide their informed consent before proceeding to the survey questions. The RTI Office of Research Protection determined that this study met the criteria for exemption from institutional review board review on July 20, 2023. This study complied with all applicable laws regarding subject privacy. The final data set was de-identified, and study results are presented in aggregate only.
